Trimodal Treatment Outcome and Survival Study of Patient Treated for High Grade Diffuse Glial Tumor
نویسندگان
1 Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey
2 Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey
3 Department of Radiation Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey
4 Department of Neurosurgery, Faculty of Medicine, Selcuk University, Konya, Turkey
5 Department of Medical Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey
6 Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey
7 Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey
8 Department of Radiation Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey
9 Department of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey
10 Department of Radiation Oncology, Ministry of Health, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey
doi
10.22034/ircmj.2024.439896.0چکیده
Background and Objectives: Surgery is the standard of care for high grade diffuse glial tumour (HGDGT) but addition of adjuvant chemo-radiotherapy improves survival in this case. The main objective of this study is to retrospectively evaluate the clinical features of diagnosis and perform overall survival analysis of patients with HGDGT’s in our department. Methods: Between April 9th, 2012 and January 24th, 2020, patients with histo-pathologically diagnosed HGDGT who received postoperative or primary radiotherapy (RT) were evaluated retrospectively. Results: 105 patients diagnosed with grade III-IV diffuse glial tumour were included. Median follow-up time was 13.6 months. The median overall survival was estimated as 13.5 months. The 1, 2 and 5 year OS rates were found to be 55.2%, 28.6% and 7.3% respectively. In univariate analysis, median OS for age groups, histopathologic groups, grades and KPS scores were showed that statistically significant difference. Multivariate analysis confirmed that younger age, unicentric tumour, grade III histology and RPA class III-IV were significant factors for OS and PFS. Conclusion: Despite maximally safe resection and combined multimodal adjuvant therapy, HGDGT’s have poor prognosis, low survival and high recurrence rates. Innovative treatments such as targeted drugs and immunotherapy in addition to RT, may offer the hope of better survival.
